Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical Trials.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39437132.
- Also identified by DOI 10.1056/EVIDctcs2300291 and PMC identifier 12153078.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AbstractIn response to the Covid-19 pandemic, the National Heart, Lung, and Blood Institute launched five multisite clinical trials testing candidate host tissue-directed medical interventions to hasten recovery, improve function, and reduce morbidity and mortality. Speed, flexibility, and collaboration were essential. This article from the Steering and Executive committees describes the Collaborating Network of Networks for Evaluating Covid-19 and Therapeutic Strategies (CONNECTS) research program that enrolled 6690 participants and evaluated 18 intervention strategies using 10 molecular agents across the care continuum (outpatient, inpatient, and post discharge), and reports lessons learned from this initiative. Successes include rapid trial execution through collaboration and adaptive platform designs. Challenges that impeded efficiency included time required to execute subcontracts, constraints on clinical research workforce, and limited research infrastructure in nonacademic settings.
Medical subject headings
- COVID-19
- Clinical Trials as Topic
- National Heart, Lung, and Blood Institute (U.S.)